Table 3.
Immunohistochemical PSMA expression.
| Overall | [177Lu]Lu- therapy | |||
|---|---|---|---|---|
| Not eligible | Eligible | p-value | ||
| Patients, n (%) | 20 (100%) | 17 (85%) | 3 (15%) | |
| PSMA IHC available, n (%) | 11 (55%) | 8 (47.1%) | 3 (100%) | |
| H-score | ||||
| Endothelial cells Periendothelial cells Tumor cells Other non-tumor cells |
50 (25-62.5) 0 10 (5-30) 10 (10-20) |
30 (17.5-52.5) 0 7.5 (5-25) 10 (8.8-20) |
65 (62.5-77.5) 0 20 (10-32.5) 20 (15-30) |
0.08 >0.99 0.73 0.35 |
IHC, immunohistochemistry; PSMA, prostate specific membrane antigen.